Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02413424 · ClinicalTrials.gov registry record · NA
Metabolic Effects of Non-nutritive Sweeteners
A NA study, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT02413424: Completed NA study, sponsored by University of Illinois at Urbana-Champaign.
NCT02413424 is a NA study that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02413424, a NA study, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this research study is to examine whether sugar-replacement sweeteners that are currently on the market (ex. Sucralose, which is in Splenda) change how well the body works to control blood sugar.
Primary Outcome
Blood samples will be collected before and for 5 hours after drinking a glucose load to determine plasma insulin and C-peptide. Insulin secretion rate will be assessed using the minimal model of Breda and collaborators.
Interventions
- OTHER Water
- DIETARY_SUPPLEMENT Sucralose
- DIETARY_SUPPLEMENT glucose load
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-07 |
| Phase | NA |
What the finished NCT02413424 record still lists
NCT02413424 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 3 interventions - of which Water is the first listed.
NCT02413424 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02413424 about?
NCT02413424 is a clinical study titled "Metabolic Effects of Non-nutritive Sweeteners". The purpose of this research study is to examine whether sugar-replacement sweeteners that are currently on the market (ex. Sucralose, which is in Splenda) change how well the body works to control blood sugar.
What is the current status of trial NCT02413424?
This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2015-04. Estimated completion is 2017-07.
What interventions are being tested in trial NCT02413424?
The interventions under investigation include: Water (OTHER), Sucralose (DIETARY_SUPPLEMENT), glucose load (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02413424?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02413424's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia